Potrero Hill Therapeutics Competitors and Similar CompaniesClear all

Potrero Hill Therapeutics's competitors and similar companies include Esteve Quimica, SynDevRx, Merck and Astellas Pharma.

	Potrero Hill Therapeutics Potrero Hill Therapeutics is a biotech company developing therapeutics for the treatment of solid tumors.	Esteve Quimica Esteve Quimica is a company developing, manufacturing, and marketing oral and injectable-non-sterile APIs (active pharmaceutical ingredient).	SynDevRx SynDevRx is a company dedicated to developing treatments for patients whose cancer is associated with metabolic dysfunction.	Merck Merck (also known as MSD) is a company that develops and manufactures medicines and vaccines for human and animal health.	Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions.
Founding Date	Founding Date N/A	Founding Date 1966	Founding Date 2007	Founding Date 1891	Founding Date 1923
Type	Type Private	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech diabetes drug development oncology pharma	Tags Healthcare diabetes drug development oncology pharma	Tags Healthcare biotech diabetes drug development oncology pharma	Tags Healthcare biotech distribution drug development pharma veterinary	Tags Healthcare diabetes drug development oncology pharma
Locations	Locations Half Moon Bay, US HQ	Locations Barcelona, ES HQ Shaoxing Shi, CN Barcelona, ES Celrà, ES	Locations Cambridge, US HQ	Locations Rahway, US HQ Munro, AR Macquarie Park, AU Krems An Der Donau, AT Wien, AT Bruxelles, BE Santa Cruz De La Sierra, BO see more	Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more
Employees	Employees 2	Employees 934	Employees 8	Employees 73,0004% increase	Employees 14,754
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 294.7 b	Valuation ($) 20.8 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $65b (FY, 2025)	Revenue (est.) ¥2.1t (FY, 2026)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods $16.4b (FY, 2025)	Cost of goods ¥213.8b (FY, 2026)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $48.6b (FY, 2025)	Gross profit ¥2t (FY, 2026)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income $18.3b (FY, 2025)	Net income ¥291.6b (FY, 2026)